Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity

Depletion of CD4+CD25high regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy

(2010) Lin Xu et al.   CANCER BIOLOGY & THERAPY

Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model

(2009) S. Wada et al.   CANCER RESEARCH

Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells

(2009) C. Jackaman et al.   EUROPEAN RESPIRATORY JOURNAL

Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice

(2009) Guillaume Darrasse-Jèze et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

(2008) Robbert G. van der Most et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor Escape Mechanism Governed by Myeloid-Derived Suppressor Cells

(2008) S. Nagaraj et al.   CANCER RESEARCH